Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Wisam N. Awadallah"'
Autor:
Magdalena M. Grabowska, Philip D. Anderson, Robert J. Matusik, Yajun Yi, Peter E. Clark, Xiuping Yu, Jagpreet S. Nanda, Renjie Jin, Thomas C. Case, Robert A. Phillips, Wisam N. Awadallah, Sarah E. Kohrt
Supplemental Figures 1-5 with figure legends embedded.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::716cd86143729129120c4ca1f8fcae1b
https://doi.org/10.1158/1535-7163.22521636.v1
https://doi.org/10.1158/1535-7163.22521636.v1
In advanced prostate cancer, resistance to androgen deprivation therapy is achieved through numerous mechanisms, including loss of the androgen receptor (AR) allowing for AR-independent growth. Therapeutic options are limited for AR-independent castr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b850b400715fc83ff27917e498c8928
https://doi.org/10.1158/1541-7786.c.6545321.v1
https://doi.org/10.1158/1541-7786.c.6545321.v1
Autor:
Magdalena M. Grabowska, Philip D. Anderson, Robert J. Matusik, Yajun Yi, Peter E. Clark, Xiuping Yu, Jagpreet S. Nanda, Renjie Jin, Thomas C. Case, Robert A. Phillips, Wisam N. Awadallah, Sarah E. Kohrt
Castration-resistant prostate cancer can be treated with the antiandrogen enzalutamide, but responses and duration of response are variable. To identify genes that support enzalutamide resistance, we performed a short hairpin RNA (shRNA) screen in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f52b8f42d03de335be79f91b8a859b
https://doi.org/10.1158/1535-7163.c.6543087.v1
https://doi.org/10.1158/1535-7163.c.6543087.v1
Autor:
Thomas C. Case, Yajun Yi, Robert J. Matusik, Philip D. Anderson, Magdalena M. Grabowska, Xiuping Yu, Jagpreet S. Nanda, Sarah E. Kohrt, Peter E. Clark, Renjie Jin, Robert A. Phillips, Wisam N. Awadallah
Publikováno v:
Mol Cancer Ther
Castration-resistant prostate cancer can be treated with the anti-androgen enzalutamide, but responses and duration of response are variable. To identify genes that support enzalutamide resistance, we performed a short hairpin RNA (shRNA) screen in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::740361cc62c1b796a598354910e797e9
https://doi.org/10.1158/1535-7163.mct-20-0244
https://doi.org/10.1158/1535-7163.mct-20-0244
Castration-resistant prostate cancer represents a continuum of phenotypes, including tumors with high levels of androgen receptor (AR) expression and activity and those which do not express AR and rely on alternative pathways for survival. The proces
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7bf0819c60f02cb2605371627f94ebf
https://doi.org/10.1101/2021.08.31.458406
https://doi.org/10.1101/2021.08.31.458406
Publikováno v:
Mol Cancer Res
In advanced prostate cancer, resistance to androgen deprivation therapy is achieved through numerous mechanisms, including loss of the androgen receptor (AR) allowing for AR-independent growth. Therapeutic options are limited for AR-independent castr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::479501f16db680c565dd90fd385ef94b
https://pubmed.ncbi.nlm.nih.gov/33188147
https://pubmed.ncbi.nlm.nih.gov/33188147
In advanced prostate cancer, resistance to androgen deprivation therapy is achieved through numerous mechanisms, including loss of the androgen receptor (AR) allowing for AR-independent growth. Therapeutic options are limited for AR-independent castr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f70ed661583c5ae7355e88a1a4263a7
Autor:
Nicole L. Miller, Wisam N. Awadallah, Thomas C. Case, Qi Liu, William A. Ricke, Marisol A. Ramirez-Solano, Emily A. Ricke, Petra Popovics, Wei Huang, Sarah E. Kohrt, Magdalena M. Grabowska, Robert J. Matusik
Publikováno v:
Journal of Urology. 203
INTRODUCTION AND OBJECTIVE:Approximately 30% of men with lower urinary tract symptoms (LUTS) are resistant to medical therapies and progress to surgical intervention. The pathological changes produ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85fa944dfeab485b7256438ef3cedb51
https://doi.org/10.1097/ju.0000000000000820.06
https://doi.org/10.1097/ju.0000000000000820.06
Autor:
Chad M. Vezina, Petra Popovics, Magdalena M. Grabowska, Sarah E. Kohrt, Marisol A. Ramirez-Solano, Wei Huang, Qi Liu, Robert J. Matusik, Emily A. Ricke, Wisam N. Awadallah, William A. Ricke, Thomas C. Case, Nicole L. Miller
Publikováno v:
Prostate
BackgroundMale lower urinary tract symptoms (LUTS) occur in more than half of men above 50 years of age. LUTS were traditionally attributed to benign prostatic hyperplasia (BPH) and therefore the clinical terminology often use LUTS and BPH interchang
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4ad4a3cb0eee3874ba22d07d7694484
Autor:
Sarah E. Kohrt, Wisam N. Awadallah, Petra Popovics, Jagpreet S. Nanda, Justin M M Cates, Magdalena M. Grabowska, Giovanna A. Giannico, Janni Mirosevich, Peter E. Clark
Publikováno v:
Prostate
BackgroundMost prostate cancers express androgen receptor (AR), and our previous studies have focused on identifying transcription factors that modify AR function. We have shown that nuclear factor I/B (NFIB) regulates AR activity in androgen-depende
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a3a53cc4a4f3bf75ced308ff50f607a
https://doi.org/10.1101/684472
https://doi.org/10.1101/684472